<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02173522</url>
  </required_header>
  <id_info>
    <org_study_id>20131034</org_study_id>
    <nct_id>NCT02173522</nct_id>
  </id_info>
  <brief_title>Phase II Investigation of Prostate Artery Embolization (PAE) Before Radical Prostatectomy in Prostate Cancer Patients</brief_title>
  <official_title>Phase II Open Label Investigation of the Safety and Efficacy of Pre-Operative Prostate Artery Embolization (PAE) Before Radical Prostatectomy in Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shivank Bhatia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merit Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Society of Interventional Radiology Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether pre-operative prostate artery embolization
      (PAE) reduces intra-operative blood loss and improves surgical outcomes among prostate cancer
      patients undergoing robot-assisted laparoscopic radical prostatectomy (RALRP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Duration of study:

      This study will enroll 20 patients, with a target enrollment period of 18 months. Patients
      who undergo prostate artery embolization (PAE) will have follow-up visits 2 weeks and 6 weeks
      after PAE. All patients in the study will have post RALRP follow-up visits at 2 weeks, 3
      months, 6 months, 9 months, and 12 months after surgery. All patients will continue to be
      followed according to the usual standard of care following the completion of the study.

      Study design:

      The first 10 patients who meet all study eligibility criteria and provide consent for
      participation in the study will receive PAE prior to RALRP. Control patients will be matched
      1:1 to PAE patients, according to risk score, and will receive RALRP without PAE. Control
      patients will be selected after all PAE patients have been enrolled, and need not meet all
      study eligibility criteria.

      The following assessments and evaluations are required for participation in this study:

      Physical exams, blood &amp; urine tests, magnetic resonance imaging (MRI), digital rectal exams
      (DREs), transrectal ultrasound (TRUS), Expanded Prostate Cancer Index Composite (EPIC)
      questionnaires, International Index of Erectile Function (IIEF) questionnaires,
      robot-assisted laparoscopic radical prostatectomy (RALRP), and pad weight tests. All patients
      enrolled in the PAE arm of the study will undergo embolization of the blood vessels that feed
      the prostate.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment difficulty
  </why_stopped>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">June 16, 2017</completion_date>
  <primary_completion_date type="Actual">June 16, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated Blood Loss During Robot-assisted Laparoscopic Radical Prostatectomy (RALRP)</measure>
    <time_frame>RALRP procedure, up to 3 hours</time_frame>
    <description>Blood loss during the robotic prostatectomy will be estimated by the surgeon performing the procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin Compared to Baseline</measure>
    <time_frame>Baseline, RALRP post operative day</time_frame>
    <description>Patients will undergo a blood test to assess their hemoglobin level prior to surgery on the day of RALRP, and again on post operative day 1 to determine the change in the hemoglobin level following surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hematocrit</measure>
    <time_frame>Baseline, RALRP post operative day 1</time_frame>
    <description>Patients will undergo a blood test to assess their hematocrit prior to surgery on the day of RALRP, and again on post operative day 1 to determine the change in the hematocrit following surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Prostate Volume</measure>
    <time_frame>Baseline, 6 weeks post PAE</time_frame>
    <description>Patients who receive PAE will undergo MRIs before PAE and 6 weeks after PAE to assess any change in prostate volume following the embolization procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients That Required Blood Transfusion</measure>
    <time_frame>RALRP procedure</time_frame>
    <description>Requirement for blood transfusion during the prostatectomy procedure will be assessed in all patients. The surgeon performing the prostatectomy will determine whether or not patients require blood transfusions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RALRP Duration</measure>
    <time_frame>RALRP procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay After RALRP</measure>
    <time_frame>48 hours post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants for Whom Prostatectomy Procedure Did Not Succeed in Removing the Entire Cancer</measure>
    <time_frame>RALRP procedure</time_frame>
    <description>Histopathology examination post RALRP will be used to determine if the prostatectomy procedure succeeded in removing the entire cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Recurrence of Prostate Cancer</measure>
    <time_frame>1 year post RALRP</time_frame>
    <description>Biochemical recurrence of prostate cancer will be determined by PSA levels 1 year following the RALRP procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to Continence</measure>
    <time_frame>An expected average of 1 week post RALRP</time_frame>
    <description>Return to continence following the RALRP procedure will be determined by the pad weight test, conducted at each follow-up visit until the patient is continent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RALRP-related Adverse Events</measure>
    <time_frame>Through 1 year post RALRP</time_frame>
    <description>Any adverse event occurring between the date of RALRP and 1 year of follow-up that the investigators determine to be related to the RALRP procedure will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAE-related Adverse Events</measure>
    <time_frame>Through 1 year post RALRP</time_frame>
    <description>Any adverse event occurring between the date of PAE and 1 year of follow-up that the investigators determine to be related to the PAE procedure will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Erectile Function at One Year Post RALRP</measure>
    <time_frame>Baseline,1 year post RALRP</time_frame>
    <description>The International Index of Erectile Function (IIEF) questionnaire is a multi-dimensional self-administered test found to be used in the clinical assessment of erectile dysfunction. It examines the 4 main domains of male sexual function. A higher score would indicated less dysfunction. The scores can range 6 to 75</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PSA Following PAE</measure>
    <time_frame>6 weeks post PAE</time_frame>
    <description>Patients who undergo PAE will have blood tests to determine the change in their PSA levels between baseline and 6 weeks post PAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histologic Changes in the Prostate After PAE</measure>
    <time_frame>Between baseline prostate biopsy and RALRP</time_frame>
    <description>The Gleason Score prostate Cancer Grading and Prognostic scoring system will be used to determine the histologic changes in the prostate tumor. Since prostate tumors are often made up of cancerous cells that have different grades, two grades are assigned to each patient. A primary grade is given to describe the cells that make up the largest area of the tumor and a secondary grade is given to describe the cells of the next largest area. The sums of the scores will be evaluated. The Gleason Score sum will range from 1 - 10, with the higher score indicating a more advanced neoplasm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Prostate artery embolization (PAE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>10 patients, matched to PAE patients by risk score, will receive RALRP without PAE. RALRP without PAE is the current standard of care treatment for prostate cancer at the Sylvester Comprehensive Cancer Center.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prostate artery embolization (PAE)</intervention_name>
    <description>Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.</description>
    <arm_group_label>Prostate artery embolization (PAE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is 45-79 years old

          -  Patient has signed informed consent

          -  Patient has biopsy-proven prostate adenocarcinoma with localized disease

          -  Patient is a candidate for robot-assisted laparoscopic radical prostatectomy (RALRP)

          -  Patient has a prostate size &gt;40 grams

        Exclusion Criteria:

          -  Active urinary tract infection

          -  History of life threatening allergy to iodinated contrast agents

          -  Any known condition that limits catheter-based intervention or is a contraindication
             to embolization (eg shunt or adverse arterial anatomy)

          -  Patient is unable to undergo MRI imaging

          -  Cardiac condition including congestive heart failure or uncontrolled arrhythmia,
             uncontrolled diabetes mellitus, significant respiratory disease, or known
             immunosuppression which required hospitalization within the previous 6 months

          -  Baseline serum creatinine level &gt; 1.8 mg/dL

          -  Baseline hemoglobin &lt; 8.0 g/dL

          -  Active cystolithiasis or prostatitis

          -  History of pelvic irradiation or radical pelvic surgery

          -  Known major iliac arterial occlusive disease

          -  Confirmed or suspected bladder cancer

          -  Urethral strictures, bladder neck contracture, or other bladder or urethral pathology
             that could limit catheterization

          -  Previous rectal surgery (other than hemorrhoidectomy) or history of rectal disease if
             the therapy or patient evaluation may potentially cause injury to sites of previous
             rectal surgery, e.g. if a transrectal probe is used

          -  Previous pelvic irradiation or radical pelvic surgery

          -  Previous prostate surgery, balloon dilatation, stent implantation, laser
             prostatectomy, hyperthermia, or any other invasive treatment to the prostate

          -  Prior transurethral resection of the prostate or other invasive therapies

          -  Coagulation disturbances not normalized by medical treatment

          -  Acute urinary retention

          -  Hypersensitivity to gelatin products

          -  Any contraindication to embolization, including intolerance to vessel occlusion
             procedures, vascular anatomy/blood flow that precludes catheter placement or embolic
             agent injection, presence/likely onset of vasospasm, presence/likely onset of
             hemorrhage, severe atheromatous disease, feeding arteries smaller than distal
             branches, arteriovenous shunt, and collateral vessel pathways endangering normal
             territories during embolization or pelvic inflammatory disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shivank Bhatia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 22, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <results_first_submitted>November 19, 2018</results_first_submitted>
  <results_first_submitted_qc>June 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2019</results_first_posted>
  <last_update_submitted>June 1, 2019</last_update_submitted>
  <last_update_submitted_qc>June 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Shivank Bhatia</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Radiology</investigator_title>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Prostate artery embolization</keyword>
  <keyword>Robot-assisted laparoscopic radical prostatectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 18, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT02173522/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prostate Artery Embolization (PAE)</title>
          <description>10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
Prostate artery embolization (PAE): Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>10 patients, matched to PAE patients by risk score, will receive RALRP without PAE. RALRP without PAE is the current standard of care treatment for prostate cancer at the Sylvester Comprehensive Cancer Center.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>subject analyzed in PAE arm 4. 0 subject analyzed in the control arm</population>
      <group_list>
        <group group_id="B1">
          <title>Prostate Artery Embolization (PAE)</title>
          <description>10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
Prostate artery embolization (PAE): Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>10 patients, matched to PAE patients by risk score, will receive RALRP without PAE. RALRP without PAE is the current standard of care treatment for prostate cancer at the Sylvester Comprehensive Cancer Center.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Estimated Blood Loss During Robot-assisted Laparoscopic Radical Prostatectomy (RALRP)</title>
        <description>Blood loss during the robotic prostatectomy will be estimated by the surgeon performing the procedure.</description>
        <time_frame>RALRP procedure, up to 3 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization (PAE)</title>
            <description>10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
Prostate artery embolization (PAE): Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Blood Loss During Robot-assisted Laparoscopic Radical Prostatectomy (RALRP)</title>
          <description>Blood loss during the robotic prostatectomy will be estimated by the surgeon performing the procedure.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin Compared to Baseline</title>
        <description>Patients will undergo a blood test to assess their hemoglobin level prior to surgery on the day of RALRP, and again on post operative day 1 to determine the change in the hemoglobin level following surgery.</description>
        <time_frame>Baseline, RALRP post operative day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization (PAE)</title>
            <description>10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
Prostate artery embolization (PAE): Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin Compared to Baseline</title>
          <description>Patients will undergo a blood test to assess their hemoglobin level prior to surgery on the day of RALRP, and again on post operative day 1 to determine the change in the hemoglobin level following surgery.</description>
          <units>G/DL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BASELINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="0.725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POST RALRP DAY 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.77" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hematocrit</title>
        <description>Patients will undergo a blood test to assess their hematocrit prior to surgery on the day of RALRP, and again on post operative day 1 to determine the change in the hematocrit following surgery.</description>
        <time_frame>Baseline, RALRP post operative day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization (PAE)</title>
            <description>10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
Prostate artery embolization (PAE): Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hematocrit</title>
          <description>Patients will undergo a blood test to assess their hematocrit prior to surgery on the day of RALRP, and again on post operative day 1 to determine the change in the hematocrit following surgery.</description>
          <units>percentage of red blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BASELINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.65" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POST RALRP DAY 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.92" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Prostate Volume</title>
        <description>Patients who receive PAE will undergo MRIs before PAE and 6 weeks after PAE to assess any change in prostate volume following the embolization procedure.</description>
        <time_frame>Baseline, 6 weeks post PAE</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization (PAE)</title>
            <description>10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
Prostate artery embolization (PAE): Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Prostate Volume</title>
          <description>Patients who receive PAE will undergo MRIs before PAE and 6 weeks after PAE to assess any change in prostate volume following the embolization procedure.</description>
          <units>cc</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.6" spread="30.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.55" spread="32.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients That Required Blood Transfusion</title>
        <description>Requirement for blood transfusion during the prostatectomy procedure will be assessed in all patients. The surgeon performing the prostatectomy will determine whether or not patients require blood transfusions.</description>
        <time_frame>RALRP procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization (PAE)</title>
            <description>10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
Prostate artery embolization (PAE): Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Required Blood Transfusion</title>
          <description>Requirement for blood transfusion during the prostatectomy procedure will be assessed in all patients. The surgeon performing the prostatectomy will determine whether or not patients require blood transfusions.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RALRP Duration</title>
        <time_frame>RALRP procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization (PAE)</title>
            <description>10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
Prostate artery embolization (PAE): Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.</description>
          </group>
        </group_list>
        <measure>
          <title>RALRP Duration</title>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay After RALRP</title>
        <time_frame>48 hours post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization (PAE)</title>
            <description>10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
Prostate artery embolization (PAE): Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay After RALRP</title>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants for Whom Prostatectomy Procedure Did Not Succeed in Removing the Entire Cancer</title>
        <description>Histopathology examination post RALRP will be used to determine if the prostatectomy procedure succeeded in removing the entire cancer.</description>
        <time_frame>RALRP procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization (PAE)</title>
            <description>10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
Prostate artery embolization (PAE): Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants for Whom Prostatectomy Procedure Did Not Succeed in Removing the Entire Cancer</title>
          <description>Histopathology examination post RALRP will be used to determine if the prostatectomy procedure succeeded in removing the entire cancer.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Recurrence of Prostate Cancer</title>
        <description>Biochemical recurrence of prostate cancer will be determined by PSA levels 1 year following the RALRP procedure.</description>
        <time_frame>1 year post RALRP</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization (PAE)</title>
            <description>10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
Prostate artery embolization (PAE): Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Recurrence of Prostate Cancer</title>
          <description>Biochemical recurrence of prostate cancer will be determined by PSA levels 1 year following the RALRP procedure.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.067" spread="0.0427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Return to Continence</title>
        <description>Return to continence following the RALRP procedure will be determined by the pad weight test, conducted at each follow-up visit until the patient is continent.</description>
        <time_frame>An expected average of 1 week post RALRP</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization (PAE)</title>
            <description>10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
Prostate artery embolization (PAE): Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.</description>
          </group>
        </group_list>
        <measure>
          <title>Return to Continence</title>
          <description>Return to continence following the RALRP procedure will be determined by the pad weight test, conducted at each follow-up visit until the patient is continent.</description>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="463" spread="496.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RALRP-related Adverse Events</title>
        <description>Any adverse event occurring between the date of RALRP and 1 year of follow-up that the investigators determine to be related to the RALRP procedure will be assessed.</description>
        <time_frame>Through 1 year post RALRP</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization (PAE)</title>
            <description>10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
Prostate artery embolization (PAE): Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.</description>
          </group>
        </group_list>
        <measure>
          <title>RALRP-related Adverse Events</title>
          <description>Any adverse event occurring between the date of RALRP and 1 year of follow-up that the investigators determine to be related to the RALRP procedure will be assessed.</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PAE-related Adverse Events</title>
        <description>Any adverse event occurring between the date of PAE and 1 year of follow-up that the investigators determine to be related to the PAE procedure will be assessed.</description>
        <time_frame>Through 1 year post RALRP</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization (PAE)</title>
            <description>10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
Prostate artery embolization (PAE): Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.</description>
          </group>
        </group_list>
        <measure>
          <title>PAE-related Adverse Events</title>
          <description>Any adverse event occurring between the date of PAE and 1 year of follow-up that the investigators determine to be related to the PAE procedure will be assessed.</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Erectile Function at One Year Post RALRP</title>
        <description>The International Index of Erectile Function (IIEF) questionnaire is a multi-dimensional self-administered test found to be used in the clinical assessment of erectile dysfunction. It examines the 4 main domains of male sexual function. A higher score would indicated less dysfunction. The scores can range 6 to 75</description>
        <time_frame>Baseline,1 year post RALRP</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization (PAE)</title>
            <description>10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
Prostate artery embolization (PAE): Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Erectile Function at One Year Post RALRP</title>
          <description>The International Index of Erectile Function (IIEF) questionnaire is a multi-dimensional self-administered test found to be used in the clinical assessment of erectile dysfunction. It examines the 4 main domains of male sexual function. A higher score would indicated less dysfunction. The scores can range 6 to 75</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" spread="8.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PSA Following PAE</title>
        <description>Patients who undergo PAE will have blood tests to determine the change in their PSA levels between baseline and 6 weeks post PAE.</description>
        <time_frame>6 weeks post PAE</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization (PAE)</title>
            <description>10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
Prostate artery embolization (PAE): Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PSA Following PAE</title>
          <description>Patients who undergo PAE will have blood tests to determine the change in their PSA levels between baseline and 6 weeks post PAE.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9125" spread="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.94" spread="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Histologic Changes in the Prostate After PAE</title>
        <description>The Gleason Score prostate Cancer Grading and Prognostic scoring system will be used to determine the histologic changes in the prostate tumor. Since prostate tumors are often made up of cancerous cells that have different grades, two grades are assigned to each patient. A primary grade is given to describe the cells that make up the largest area of the tumor and a secondary grade is given to describe the cells of the next largest area. The sums of the scores will be evaluated. The Gleason Score sum will range from 1 - 10, with the higher score indicating a more advanced neoplasm.</description>
        <time_frame>Between baseline prostate biopsy and RALRP</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization (PAE)</title>
            <description>10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
Prostate artery embolization (PAE): Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.</description>
          </group>
        </group_list>
        <measure>
          <title>Histologic Changes in the Prostate After PAE</title>
          <description>The Gleason Score prostate Cancer Grading and Prognostic scoring system will be used to determine the histologic changes in the prostate tumor. Since prostate tumors are often made up of cancerous cells that have different grades, two grades are assigned to each patient. A primary grade is given to describe the cells that make up the largest area of the tumor and a secondary grade is given to describe the cells of the next largest area. The sums of the scores will be evaluated. The Gleason Score sum will range from 1 - 10, with the higher score indicating a more advanced neoplasm.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.25" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post RALP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" spread="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Prostate Artery Embolization (PAE)</title>
          <description>10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
Prostate artery embolization (PAE): Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu Like Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Edema Limbs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Wound Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder Spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urinary Urgency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Acute Kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shivank Bhatia</name_or_title>
      <organization>University of Miami</organization>
      <phone>305-243-7500</phone>
      <email>sbhatia1@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

